...
机译:Pt(Ⅳ)前药优先靶向吲哚胺-2,3-双加氧酶,提供增强的卵巢癌免疫化学疗法。
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States;
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States;
The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States;
The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States;
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States, The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States;
机译:吲哚胺-2,3-双加氧酶是一种抑制自然杀伤细胞功能的免疫抑制酶,可作为卵巢癌治疗的有用靶标
机译:生物素-PT(iv) - 吲哚苄啶杂种:A靶向抗癌前药,提供增强的癌细胞摄取和逆转顺铂抗性
机译:靶向抑制磷脂酰肌醇3激酶p110β(而非p110α)可增强化疗耐药性卵巢癌的凋亡和对紫杉醇的敏感性
机译:剖析卵巢癌揭示了卵巢癌亚型共有的共同特征:寻找治疗药物靶点的网络生物学方法
机译:肽J18的修饰以增强卵巢癌细胞的靶向性
机译:Platinum(IV)前药优先靶向IDO以提供增强的卵巢癌免疫化学疗法
机译:pt(IV)前药优先靶向吲哚胺-2,3-双加氧酶,提供增强的卵巢癌免疫化疗